Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Postoperative complications
研究概览
简要总结
Liver resection have been a primary treatment option for lesions found in the liver. With improvements in surgical technique and perioperative patient management, morbidity and mortality related to liver resection have been greatly reduced. However, many patients with hepatocellular carcinoma have underlying liver disease. Severity of underlying liver disease plays an important role in decision making of resection extent. Therefore, liver failure and decreased liver function following liver resection still remains to be an critical issue.
Postresection liver failure is generally defined by serum total bilirubin greater than 3mg/dL and prothrombin time of less than 50% of normal (INR >1.7). Pathophysiology of postresection liver failure is not yet well known. However, sepsis after liver resection, small-for-size syndrome (SFSS), and ischemia/reperfusion injury are known to have important roles in persistant liver injury after resection.
After a liver resection, kupffer cells are drastically decreased and innate immunity of the patient is also damaged. This process causes the patient to be vulnerable to infection. In addition, with continuous endotoxin secretion, dysfunction in kupffer cells are triggered and liver regeneration is affected.
Complex mechanisms leading to dysfunctional kupffer cells and apoptosis and necrosis of hepatocytes are mediated by neutrophils, complement, reactive oxygen species, and acute inflammatory cytokines.
Recent studies have reported on many promising effects of the synthetic protease inhibitor, such as Gabexate mesilate. These include antioxidant effect, inhibition of acute inflammatory cytokine reaction, and anticoagulatory property. Based on these effects, synthetic protease inhibitor have gained attention in the role of hepatocyte protection after liver resection.
Currently, there is a report on the hepatocyte protective effects of Gabexate Mesilate on ischemia/reperfusion injury caused by the Pringle maneuver. However, with the advances in surgical technique and equipment, many surgeons now perform liver resection without Pringle maneuver. Therefore, this study was designed to determine effects of Gabexate Mesilate in the liver resection performed without Pringle maneuver.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All liver tumors that require resection of more than two segments of the liver.
- •Age ≥20 and ≤80
- •General performance status: the Karnofsky score> 70% or ECOG 0-1
排除标准
- •Hepatic duct reconstruction was performed
- •ASA (American society of anesthesiologists' physical status classification) score: ≥3
- •Patients with drug or alcohol addiction
- •Patients showing low compliance
- •Patients who not want to involve the clinical trial
- •Patients who are unable to read or understand the informed consent, sign a consent form (eg, mental retardation, blindness, illiteracy, foreign, etc.)
研究组 & 干预措施
Placebo group
hepatectomy without Gabexate Mesilate
干预措施: hepatectomy with dextrose water (Drug)
Preoperative Gabexate Mesilate group
Gabexate Mesilate administered from the preoperative day
干预措施: Preoperative Gabexate Mesilate group (Drug)
Intraoperative Gabexate Mesilate group
Gabexate Mesilate administered from the operative day
干预措施: Intraoperative Gabexate Mesilate group (Drug)
结局指标
主要结局
Postoperative complications
时间窗: Within the first 30 days after surgery
次要结局
- Liver function recovery time(4 weeks)
- length of hospitalization(4 weeks)
